The most advanced IL-10 therapy has been the treatment of cancer patients with a PEGylated recombinant human IL-10 (PEG-rHuIL-10), which has been shown to suppress tumour-associated immunity, improve clinical outcome (99). The gene discussed is IL10; the disease is neoplasm.